Comparative osteogenic performance of Chinese hamster ovary cell-derived versus Escherichia coli-derived recombinant human bone morphogenetic protein-2
Charles Matthews, Lyndsey Johnson, Whitney Holden, John von Benecke · 2026
Read Comparative osteogenic performance of Chinese hamster ovary cell-derived versus Escherichia coli-derived recombinant human bone morphogenetic protein-2 by Charles Matthews, Lyndsey Johnson, Whitney Holden, John von Benecke (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13268706.txt.
Description
Charles Matthews and colleagues present a 2026 study comparing two factory systems for making a bone-growth protein used in surgery. The approved product is grown in hamster ovary cells; growing it in E. coli bacteria could be cheaper. The team screened four bacterial-made versions in cell tests, picked the strongest, and compared it with the hamster-cell product in 15 rats. Sponges carrying the protein were placed in muscle pouches for four weeks.
The winning bacterial version beat the standard in cell tests and formed roughly ten times more bone in rats, with more mature structure under the microscope. But the four bacterial versions varied widely among themselves. The authors warn that potency cannot be assumed from protein weight alone: each supplier's product needs its own testing before clinical trust.
Catalog record
| CREATOR | Charles Matthews, Lyndsey Johnson, Whitney Holden, John von Benecke |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38837 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |